Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria.
Ayuk F et al. Ann Hematol. 2015 Jul 24. [Epub ahead of print].
18F-FDG and 18F-NaF PET/CT Findings of a Multiple Myeloma Patient With Thyroid Cartilage Involvement.
Oral A et al. Clin Nucl Med. 2015 Jul 22. [Epub ahead of print].
Tumor associated macrophages (TAMs) and extraczellular matrix metalloproteinase inducer (EMMPRIN) in prognosis of multiple Myeloma.
Panchabhai S et al. Leukemia. 2015 Jul 23. doi: 10.1038/leu.2015.191. [Epub ahead of print].
Flow cytometry quality requirements for monitoring of minimal disease in plasma cell myeloma.
Oldaker TA et al. Cytometry B Clin Cytom. 2015 Jul 22. doi: 10.1002/cyto.b.21276. [Epub ahead of print].
Quantitative Analysis of MR Imaging to Assess Treatment Response for Patients with Multiple Myeloma by Using Dynamic Intensity Entropy Transformation: A Preliminary Study.
Zhou C et al. Radiology. 2015 Jul 20:142804. [Epub ahead of print].
Minimal residual disease testing after stem cell transplantation for multiple myeloma.
Sherrod AM et al. one Marrow Transplant. 2015 Jul 20. doi: 10.1038/bmt.2015.164. [Epub ahead of print].
A Dual Color Immunohistochemistry Assay for Measurement of Cereblon in Multiple Myeloma Patient Samples.
Ren Y et al. Appl Immunohistochem Mol Morphol. 2015 Jul 16. [Epub ahead of print].
Apparent Diffusion Coefficient Maps Integrated in Whole-Body MRI Examination for the Evaluation of Tumor Response to Chemotherapy in Patients with Multiple Myeloma.
Bonaffini PA et al. Acad Radiol. 2015 Jul 13. pii: S1076-6332(15)00249-4. doi: 10.1016/j.acra.2015.05.011. [Epub ahead of print].
N-terminal pro-C-type natriuretic peptide in serum associated with bone destruction in patients with multiple myeloma.
Mylin AK et al. Biomark Med. 2015 Jul;9(7):679-89. doi: 10.2217/bmm.15.35.
High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders.
Caivano A et al. Tumour Biol. 2015 Jul 9. [Epub ahead of print].
Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myeloma.
Binder M et al. Am J Hematol. 2015 Jul 6. doi: 10.1002/ajh.24107. [Epub ahead of print].
Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic Service (HMDS).
Rawstron AC et al. Cytometry B Clin Cytom. 2015 Jul 3. doi: 10.1002/cyto.b.21271. [Epub ahead of print].
Utility of Immunophenotyping of Plasma Cells in Multiple Myeloma.
Gertz MA et al. Leuk Lymphoma. 2015 Jul 2:1-6. [Epub ahead of print].
Intravoxel Incoherent Motion Diffusion-weighted Imaging of Multiple Myeloma Lesions: Correlation with Whole-Body Dynamic Contrast Agent-enhanced MR Imaging.
Bourillon C et al. Radiology. 2015 Jul 1:141728. [Epub ahead of print].
Utility of CD54, CD229 and CD319 for the identification of plasma cells in patients with clonal plasma cell diseases.
Pojero F et al. Cytometry B Clin Cytom. 2015 Jun 30. doi: 10.1002/cyto.b.21269. [Epub ahead of print].
A Bone to Pick Regarding Use of Magnetic Resonance Imaging to Begin Treatment in Patients With Asymptomatic Multiple Myeloma.
Cooper DL. J Clin Oncol. 2015 Jul 27. pii: JCO.2015.61.7712. [Epub ahead of print].
Prognostic significance of increased bone marrow microcirculation in newly diagnosed multiple myeloma: results of a prospective DCE-MRI study.
Merz M et al. Eur Radiol. 2015 Jul 29. [Epub ahead of print].